Anti-JO-1 Antibodies by EIA

Lung

Report in 48Hrs

At Home

No Fasting Required

Details

Autoantibody test against histidyl-tRNA synthetase.

₹2,220₹3,171

30% OFF

Anti-JO-1 Antibodies by EIA - Comprehensive Test Information Guide

Section 1: Why is it done?
- Test Description: This test detects anti-JO-1 antibodies (also known as anti-histidyl-tRNA synthetase antibodies) using enzyme immunoassay (EIA). Anti-JO-1 is an autoantibody that targets the histidyl-transfer RNA synthetase enzyme found in muscle and other tissues.
- Primary Indications: Suspected myositis or inflammatory muscle disease Evaluation of polymyositis or dermatomyositis Assessment of anti-synthetase syndrome Diagnosis of interstitial lung disease with myositis features Investigation of proximal muscle weakness with systemic symptoms Screening for autoimmune connective tissue diseases
- Typical Timing: Ordered during initial evaluation of unexplained muscle weakness or inflammatory symptoms Performed when other myositis antibodies are being tested Used as part of comprehensive autoimmune panel workup May be repeated to monitor disease activity or treatment response
Section 2: Normal Range
- Reference Range: Negative or < 1.0 Index (varies by laboratory) Most laboratories report results as either negative or positive Some labs use index values where < 0.9 is considered negative
- Units of Measurement: Index units (typically 0.0 to 1.0 scale) Qualitative (Negative/Positive) Quantitative titers in some laboratories
- Result Interpretation: Negative/Normal: Absence of anti-JO-1 antibodies; consistent with healthy individuals or those without anti-synthetase syndrome Positive: Presence of anti-JO-1 antibodies; indicates autoimmune response to histidyl-tRNA synthetase Equivocal: Results in gray zone that may require retesting or clinical correlation Higher titers may suggest more active disease or higher disease burden
- Clinical Significance: Positive results are relatively specific for myositis and anti-synthetase syndrome Anti-JO-1 is one of the most common myositis-specific antibodies Found in approximately 20-30% of myositis patients Present in up to 55% of polymyositis cases
Section 3: Interpretation
- Positive Result Interpretation: Strong indicator of myositis (polymyositis or dermatomyositis) Associated with anti-synthetase syndrome which includes myositis, interstitial lung disease, arthritis, and Raynaud phenomenon Suggests active autoimmune process targeting muscle tissue Highly specific for inflammatory muscle disease (high positive predictive value) May correlate with disease severity and extent of muscle involvement
- Negative Result Interpretation: Does not exclude myositis or inflammatory muscle disease Other myositis antibodies may be present (anti-Mi2, anti-SRP, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ) Muscle weakness may be due to other etiologies (metabolic, toxic, neurogenic, structural) Patients with seronegative myositis may still have myositis-specific disease Approximately 70% of myositis patients are anti-JO-1 negative
- Factors Affecting Results: Disease activity level and phase Duration of disease (may appear early in disease course) Current treatment and immunosuppressive therapy Disease overlap features Sample handling and storage Hemolysis or lipemia in specimen Laboratory-specific assay variations
- Clinical Significance Patterns: Positive anti-JO-1 + proximal muscle weakness + elevated muscle enzymes = strong indication of myositis Positive anti-JO-1 + interstitial lung disease = anti-synthetase syndrome likely Positive anti-JO-1 + Raynaud phenomenon + arthritis = classic anti-synthetase syndrome Positive anti-JO-1 in asymptomatic individual = increased risk for developing myositis (requires clinical monitoring) Serial antibody levels may not correlate with disease activity in all patients
Section 4: Associated Organs
- Primary Organ Systems Involved: Skeletal Muscle: Primary target organ; undergoes inflammatory destruction Lungs: Interstitial lung disease with pulmonary fibrosis Joints: Non-erosive arthritis commonly involving hands and shoulders Skin: Involved in dermatomyositis presentations Heart: Myocarditis and conduction abnormalities Esophagus: Dysphagia and esophageal dysfunction
- Associated Diseases and Conditions: Polymyositis: Progressive proximal muscle weakness Dermatomyositis: Muscle inflammation with characteristic skin manifestations Anti-Synthetase Syndrome: Complex manifestation with myositis, ILD, arthritis, mechanics hands, fever Interstitial Lung Disease (ILD): Progressive pulmonary fibrosis Non-specific interstitial pneumonia (NSIP) Organizing pneumonia Adult-onset asthma (associated finding) Systemic Sclerosis overlap features
- Potential Complications from Abnormal Results: Progressive muscle weakness and loss of function Respiratory compromise from interstitial lung disease Pulmonary fibrosis with progressive dyspnea Aspiration risk from esophageal dysmotility Dysphagia and malnutrition Cardiac arrhythmias and myocarditis Joint deformities from chronic arthritis Respiratory failure in advanced lung disease Rhabdomyolysis and acute kidney injury (severe cases) Social and occupational disability
- Risk Features Associated with Anti-JO-1: Higher risk of severe lung involvement compared to seronegative myositis Increased likelihood of interstitial lung disease development Greater prevalence of arthritis component More common in women than men Often presents with acute onset May have more aggressive clinical course requiring intensive treatment
Section 5: Follow-up Tests
- Recommended Follow-up Tests: Other Myositis Antibodies: Anti-Mi2, anti-SRP, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ Muscle Enzymes: CK (creatine kinase), LDH, AST, ALT, myoglobin Inflammatory Markers: ESR (erythrocyte sedimentation rate), CRP (C-reactive protein) Rheumatologic Panel: ANA, RF (rheumatoid factor), anti-CCP Comprehensive Metabolic Panel: Electrolytes, calcium, phosphate, renal function Liver Function Tests: AST, ALT, bilirubin, albumin Complete Blood Count: Assess for cytopenias
- Imaging and Diagnostic Studies: Electromyography (EMG): Assess muscle electrical activity and denervation Muscle Biopsy: Confirm myositis diagnosis (inflammatory infiltration pattern) MRI of Muscles: Identify inflammation, edema, fatty infiltration patterns Chest CT: Evaluate for interstitial lung disease and pulmonary fibrosis Pulmonary Function Tests (PFTs): Assess diffusion capacity and restrictive pattern High Resolution CT (HRCT) of Chest: Detailed lung imaging Echocardiography: If cardiac involvement suspected
- Monitoring Schedule for Positive Results: Initial phase (diagnosis): Baseline labs within 1-2 weeks During active treatment: Monthly muscle enzyme monitoring Early disease: Every 3 months for first 6-12 months Established disease: Every 3-6 months for CK monitoring Annually: Comprehensive reassessment including pulmonary function As needed: With change in symptoms or clinical deterioration During therapy adjustment: Increased frequency to assess response
- Related Complementary Tests: Repeat anti-JO-1: May be performed to assess disease activity in some centers (not routinely recommended for monitoring) Thyroid Antibodies: Rule out associated thyroid disease Other Autoimmune Markers: Screen for overlap syndromes Cancer Screening: Dermatomyositis patients require malignancy screening Cardiac Biomarkers: Troponin if myocarditis suspected Urinalysis: Screen for rhabdomyolysis in severe cases
Section 6: Fasting Required?
- Fasting Requirement: No - Fasting is NOT required for anti-JO-1 antibody testing by EIA
- Patient Preparation Instructions: Patient may eat and drink normally before the test No fasting period is necessary Standard blood draw requirements apply Arm should be relatively relaxed before venipuncture Wear comfortable, loose-fitting clothing to facilitate blood draw Arrive well-hydrated to ensure adequate venous access
- Medications: No specific medications need to be avoided prior to testing Continue all regular medications as prescribed Immunosuppressive drugs do not interfere with antibody detection Corticosteroids and other myositis treatments do not preclude testing Inform laboratory technician of any recent immunizations or blood products
- Sample Collection Requirements: Blood collection: 5-10 mL of serum in appropriate tube (typically SST or similar) Sample must be handled according to laboratory specifications Allow blood to clot for 20-30 minutes if using serum tube Centrifuge appropriately and separate serum from cells Avoid hemolysis by proper collection technique Store at room temperature or refrigerate per lab instructions Transport to laboratory promptly (usually within 24 hours) Avoid repeated freeze-thaw cycles
- Additional Considerations: Blood draw timing: Can be performed at any time of day Stress may slightly elevate some inflammatory markers but does not affect antibody testing Recent exercise does not significantly impact results Menstrual cycle does not affect antibody detection Recent infections: No need to delay testing; antibodies are not transient markers Confirm ordering physician's specific instructions or institutional requirements

How our test process works!